Patents by Inventor Kensuke Nakamura

Kensuke Nakamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12219688
    Abstract: A dielectric barrier plasma generator includes: a dielectric substrate, a high-voltage electrode provided on a first surface of the dielectric substrate, a low-voltage electrode provided to face a second surface of the dielectric substrate, a power introduction section provided at a first end of the high-voltage electrode, a gas channel formed from a first end to a second end thereof between the dielectric substrate and the low-voltage electrode to allow gas to flow from the first end of the gas channel to the second end thereof, and a blowout outlet formed at the second end of the gas channel to blow out the gas that has flown through the gas channel and plasma that has been generated in the gas channel. The dielectric substrate includes a portion having a thickness being thinner when being closer to the blowout outlet.
    Type: Grant
    Filed: January 18, 2021
    Date of Patent: February 4, 2025
    Assignee: Ushio Denki Kabushiki Kaisha
    Inventors: Takahiro Hiraoka, Kensuke Nakamura, Takanori Samejima
  • Publication number: 20240400681
    Abstract: Provided are methods for producing a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert human T cell suppression function.
    Type: Application
    Filed: July 9, 2024
    Publication date: December 5, 2024
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Ryuta Mukasa, Kensuke Nakamura, Sumie Muramatsu, Naoyuki Makita
  • Publication number: 20240381517
    Abstract: The dielectric barrier discharge plasma generator includes: a dielectric substrate that exhibits a plate shape extending in a first direction and has a first surface and a second surface located on an opposite side of the first surface in a second direction orthogonal to the first direction; a first electrode disposed on the dielectric substrate on a side of the first surface; a second electrode disposed at a position separated from the second surface of the dielectric substrate in the second direction; a gas flow path that is formed by a gap between the dielectric substrate and the second electrode and through which a gas flows in a third direction orthogonal to the first direction and the second direction; and an outlet provided at a first end which is one end portion of the gas flow path in the third direction.
    Type: Application
    Filed: February 28, 2022
    Publication date: November 14, 2024
    Applicant: Ushio Denki Kabushiki Kaisha
    Inventors: Kensuke NAKAMURA, Takahiro HIRAOKA
  • Publication number: 20240299573
    Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.
    Type: Application
    Filed: April 8, 2024
    Publication date: September 12, 2024
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA, Mitsuhiro IWAMOTO, Naoya HARADA, Tomoko TERAUCHI, Daisuke OKAJIMA, Kensuke NAKAMURA, Hiroaki UCHIDA, Hirofumi HAMADA
  • Publication number: 20240294660
    Abstract: An anti-SIRP? antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRP? to inhibit binding of human SIRP? to CD47.
    Type: Application
    Filed: May 10, 2024
    Publication date: September 5, 2024
    Applicants: National University Corporation Kobe University, Daiichi Sankyo Company, Limited
    Inventors: Takashi Matozaki, Mayumi Sue, Kensuke Nakamura, Chigusa Yoshimura
  • Patent number: 12071478
    Abstract: Provided are methods for treatment or prevention of an autoimmune disease that comprise administering a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: August 27, 2024
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Ryuta Mukasa, Kensuke Nakamura, Sumie Muramatsu, Naoyuki Makita
  • Patent number: 12024566
    Abstract: An anti-SIRP? antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRP? to inhibit binding of human SIRP? to CD47.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: July 2, 2024
    Assignees: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Takashi Matozaki, Mayumi Sue, Kensuke Nakamura, Chigusa Yoshimura
  • Publication number: 20240182569
    Abstract: To provide a stable bispecific molecule. A Fab that specifically binds to CD3, the Fab comprising the following CDRH1 to 3 and CDRL1 to 3: CDRH1 consisting of the amino acid sequence represented by SEQ ID NO: 32; CDRH2 consisting of the amino acid sequence represented by SEQ ID NO: 33; CDRH3 consisting of the amino acid sequence represented by SEQ ID NO: 34; CDRL1 consisting of the amino acid sequence represented by SEQ ID NO: 35; CDRL2 consisting of the amino acid sequence represented by SEQ ID NO: 36; and CDRL3 consisting of the amino acid sequence represented by SEQ ID NO: 37.
    Type: Application
    Filed: March 28, 2022
    Publication date: June 6, 2024
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Makiko NAKAYAMA, Kensuke NAKAMURA, Shinji FURUZONO, Ryota MATSUMOTO
  • Patent number: 11952423
    Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.
    Type: Grant
    Filed: May 16, 2023
    Date of Patent: April 9, 2024
    Assignees: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroshi Shiku, Yasushi Akahori, Kento Tanaka, Ayaka Yatsu, Junya Ichikawa, Toshiaki Ohtsuka, Shiho Kozuma, Ryuji Hashimoto, Makiko Nakayama, Naoya Shinozaki, Kensuke Nakamura, Ichiro Watanabe, Shinji Furuzono
  • Publication number: 20230348616
    Abstract: An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.
    Type: Application
    Filed: March 29, 2021
    Publication date: November 2, 2023
    Applicants: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroshi SHIKU, Yasushi AKAHORI, Kento TANAKA, Ayaka YATSU, Junya ICHIKAWA, Toshiaki OHTSUKA, Shiho KOZUMA, Ryuji HASHIMOTO, Makiko NAKAYAMA, Naoya SHINOZAKI, Kensuke NAKAMURA, Ichiro WATANABE, Shinji FURUZONO
  • Publication number: 20230287119
    Abstract: The present invention provides a novel antibody binding to human CD3, and a molecule having antigen binding activity that includes the antibody. The present invention provides a novel antibody binding to human CD3, a molecule having antigen binding activity that includes the antibody, and a pharmaceutical composition having cytotoxic activity that includes the antibody or the molecule as an active ingredient.
    Type: Application
    Filed: April 3, 2023
    Publication date: September 14, 2023
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Tohru TAKAHASHI, Chigusa YOSHIMURA, Shiho KOZUMA, Kensuke NAKAMURA, Chikako SUZUKI, Junya ICHIKAWA
  • Publication number: 20230287121
    Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.
    Type: Application
    Filed: May 16, 2023
    Publication date: September 14, 2023
    Applicants: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroshi SHIKU, Yasushi AKAHORI, Kento TANAKA, Ayaka YATSU, Junya ICHIKAWA, Toshiaki OHTSUKA, Shiho OKZUMA, Ryuji HASHIMOTO, Makiko NAKAYAMA, Naoya SHINOZAKI, Kensuke NAKAMURA, Ichiro WATANABE, Shinji FURUZONO
  • Publication number: 20230248819
    Abstract: The present invention provides a vaccine for preventing and/or treating infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The present invention relates to a lipid particle encapsulating a nucleic acid molecule capable of expressing the S protein and/or a fragment thereof of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the lipid comprises a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each independently represent a C1-C3 alkyl group; L1 represents a C17-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; L2 represents a C10-C19 alkyl group which may have one or a plurality of C2-C4 alkanoyloxy groups or a C10-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; and p is 3 or 4.
    Type: Application
    Filed: June 10, 2021
    Publication date: August 10, 2023
    Inventors: Yoshihiro KAWAOKA, Masaki IMAI, Seiya YAMAYOSHI, Ken ISHII, Kouji KOBIYAMA, Eiko NAMBA, Tatsuya OKA, Miyuki TOZUKA, Nao JONAI, Yoshikuni ONODERA, Fumihiko TAKESHITA, Takashi SUZUKI, Takako NIWA, Makoto KOIZUMI, Kensuke NAKAMURA
  • Publication number: 20230226205
    Abstract: It is an object of the present invention to provide an antibody binding to CDH6 and having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. The present invention provides an anti-CDH6 antibody having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.
    Type: Application
    Filed: July 26, 2022
    Publication date: July 20, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Atsuko SAITO, Tsuyoshi HIRATA, Kensuke NAKAMURA
  • Publication number: 20230212306
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
    Type: Application
    Filed: December 27, 2022
    Publication date: July 6, 2023
    Applicants: Daiichi Sankyo Company, Limited, The University of Tokyo
    Inventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
  • Publication number: 20230158452
    Abstract: A gas treatment method includes: a process (a) of allowing gas to be treated in which a target substance to be treated is mixed with air to pass through inside a housing, the target substance to be treated exhibiting volatility at room temperature and belonging to at least one substance selected from a group consisting of carbon compounds, nitrogen compounds, and sulfur compounds; a process (b) of introducing ozone into a space through which the gas to be treated flows inside the housing at 200° C. or lower; a process (c) of stirring the gas to be treated after the process (b); and a process (d) of heating the gas to be treated to 300° C. or higher after executing the process (c).
    Type: Application
    Filed: June 15, 2021
    Publication date: May 25, 2023
    Applicant: Ushio Denki Kabushiki Kaisha
    Inventors: Yuichi Otsuka, Takahiro Hiraoka, Masaki Miura, Kensuke Nakamura
  • Patent number: 11628223
    Abstract: A novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines represented by the [Formula 24], [Formula 25], [Formula 26], and/or [Formula 27].
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: April 18, 2023
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Narihiro Toda, Yusuke Ota, Fuminao Doi, Masaki Meguro, Ichiro Hayakawa, Shinji Ashida, Takeshi Masuda, Takashi Nakada, Mitsuhiro Iwamoto, Naoya Harada, Tomoko Terauchi, Daisuke Okajima, Kensuke Nakamura, Hiroaki Uchida, Hirofumi Hamada
  • Patent number: 11618785
    Abstract: The present invention provides a novel antibody binding to human CD3, and a molecule having antigen binding activity that includes the antibody. The present invention provides a novel antibody binding to human CD3, a molecule having antigen binding activity that includes the antibody, and a pharmaceutical composition having cytotoxic activity that includes the antibody or the molecule as an active ingredient.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: April 4, 2023
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Tohru Takahashi, Chigusa Yoshimura, Shiho Kozuma, Kensuke Nakamura, Chikako Suzuki, Junya Ichikawa
  • Publication number: 20230100544
    Abstract: A dielectric barrier plasma generator includes: a dielectric substrate, a high-voltage electrode provided on a first surface of the dielectric substrate, a low-voltage electrode provided to face a second surface of the dielectric substrate, a power introduction section provided at a first end of the high-voltage electrode, a gas channel formed from a first end to a second end thereof between the dielectric substrate and the low-voltage electrode to allow gas to flow from the first end of the gas channel to the second end thereof, and a blowout outlet formed at the second end of the gas channel to blow out the gas that has flown through the gas channel and plasma that has been generated in the gas channel. The dielectric substrate includes a portion having a thickness being thinner when being closer to the blowout outlet.
    Type: Application
    Filed: January 18, 2021
    Publication date: March 30, 2023
    Applicant: Ushio Denki Kabushiki Kaisha
    Inventors: Takahiro Hiraoka, Kensuke Nakamura, Takanori Samejima
  • Publication number: 20230084707
    Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.
    Type: Application
    Filed: April 5, 2022
    Publication date: March 16, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA, Mitsuhiro IWAMOTO, Naoya HARADA, Tomoko TERAUCHI, Daisuke OKAJIMA, Kensuke NAKAMURA, Hiroaki UCHIDA, Hirofumi HAMADA